Phase I study of intravenous 4-hydroxyanisole
- 31 December 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (8-9) , 1362-1364
- https://doi.org/10.1016/0959-8049(92)90520-c
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Melanogenesis: a realistic target for antimelanoma therapy?European Journal of Cancer and Clinical Oncology, 1991
- Mechanism of toxicity of the antimelanoma drug 4-hydroxyanisole in mouse hepatocytesEuropean Journal of Cancer and Clinical Oncology, 1991
- Reaction kinetics of 4-methoxy ortho benzoquinone in relation to its mechanism of cytotoxicity: a pulse radiolysis studyBiochemical Pharmacology, 1990
- Free Radical Intermediates in the Oxidation of N-Methylhydroxylamine and N,N-Dimethylhydroxylamine by OxyhemoglobinFree Radical Research Communications, 1990
- Major Primary Cytotoxic Product of 4‐Hydroxyanisole Oxidation by Mushroom Tyrosinase Is 4‐Methoxy Ortho BenzoquinonePigment Cell Research, 1988
- Hydroxyanisole‐induced regression of the Harding‐Passey melanoma in miceThe Journal of Pathology, 1977
- Mechanism of pigment‐cell toxicity produced by hydroxyanisoleThe Journal of Pathology, 1970
- Hydroxyanisole depigmentation: In‐vivo studiesThe Journal of Pathology, 1969
- Hydroxyanisole depigmentation: In‐vitro studiesThe Journal of Pathology, 1969